Acinetobacter baumannii

Background:

——————————————————————–
Non-fermenting Gram-negative bacilli   
——————————————————————–
[cannot catabolize glucose and therefore are not able to ferment. Non-spore forming.]
>Acinetobacter baumannii led
>Achromobacter xylosoxidans
>Bordetella pertussis
>Burkholderia species:
     1] Burkholderia cepacia (also known as Pseudomonas cepacia) –  important
            pathogen of pulmonary infections in people with cystic fibrosis.
     2] Burkholderia pseudomallei (also known as Pseudomonas pseudomallei) 
>Elizabethkingia meningoseptica (Previously Chryseobacterium meningosepticum)
>Moraxella catarrhalis (formerly known as Branhamella catarrhalis)
>Pseudomonas aeruginosa
>Stenotrophomonas maltophilia (Initially classified as Pseudomonas maltophilia)

Acinetobacter baumannii:   

  • -Can be an opportunistic pathogen in humans.  
  • -Increasingly important as a hospital derived (nosocomial) infection . 
  • -A. baumannii is part of the ACB complex which are difficult to speciate (A. baumannii, A. calcoaceticus, and Acinetobacter genomic species 13TU).
  • -Has been identified as an ESKAPE pathogen which have a high rate of antibiotic resistance and are responsible for the majority of nosocomial infections: (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species).
  • Source: https://en.wikipedia.org/wiki/Acinetobacter

top of page

Therapy:

Important considerations:  The choice of an agent should be based on local antimicrobial sensitivities, site of infection, cost, and comorbid conditions.   Generally, the most common agents/regimens are listed first.  Listed dosages may need to be adjusted for renal dysfunction.  

  1. Ceftazidime 2 grams IV q8h
  2. Cefepime 2 grams IV q8h
  3. Ampicillin-sulbactam (Unasyn®)  3 grams IV q6h
  4. Imipenem 500mg IV every 6 hours [Range: 250-1000 mg q6-8h]
  5. Meropenem 0.5 – 1 gram IV q8h  (life-threatening infection -unlabeled use: 2 grams IV q8h)
  6. Carbapenemase producing strains –
    • Colistimethate (colistin base): 2.5 – 5mg/kg/day in 2-4 divided doses. Max 5 mg/kg/day   PLUS   [ Meropenem 1 gram IV q8h  OR  Imipenem 500mg IV every 6 hours [Range: 250-1000 mg q6-8h]

Antibiotics used in combination with agents listed above for resistant
infections or severe disease
:

  1. Gentamicin or Tobramycin 1 to 2.5 mg/kg IV q8-12h or consider high-dose extended-interval dosing:  5 to 7 mg/kg q24-48h.  Adjust dosing frequency based on estimated clearance.
  2. Amikacin 5 to 7.5 mg/kg IV q8h or consider high-dose extended-interval dosing: 15-20 mg/kg q24-48h.  Adjust dosing frequency based on estimated clearance.
  3. Ciprofloxacin 400mg IV q8h

  

Disclaimer

The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user’s use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer